Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. (Q54630883)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

author name string

Xabier Garcia-Albeniz

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Virginia Alonso-Espinaco

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Vicente Alonso

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Pilar Escudero

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Carlos Fernández-Martos

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Rosa Gallego

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Pere Gascón

8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Sergi Castellví-Bel

9

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Joan Maurel

10

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

publication date

23 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

32

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

417-424

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

https://scigraph.springernature.com/pub.10.1007/s13277-010-0136-3

0 references

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Matrix metalloproteinase-7 expression in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Matrix metalloproteinase-7 and epidermal growth factor receptor mediate hypoxia-induced extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase activation and subsequent proliferation in bladder smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

RAF/RAS oncogenes and mismatch-repair status

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0136-3

21 January 2018

Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor Antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13277-010-0136-3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21104178

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54630883&oldid=1566584736"